Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: Response, toxicity, quality of life, and survival

Cancer

Volumn 77, Issue 10, 1996, Pages 1978-1985

  Bamias, Aris ^a   Hill, Mark E ^a   Cunningham, David ^a,b   Norman, Andrew R ^a   Ahmed, Fareeda Y ^a   Webb, Andrew ^a   Watson, Maggie ^a   Hill, Andrea S ^a   Nicolson, Marianne C ^a   O'Brien, Mary E ^a   Evans, T Christopher ^a   Nicolson, Viola ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b RMH   (United Kingdom)

Author keywords

chemotherapy; esophageal carcinoma; gastric carcinoma; infusional treatment; neoadjuvant chemotherapy; quality of life

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SCREENING; ESOPHAGUS CARCINOMA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; QUALITY OF LIFE; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 15844425222     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960515)77:10<1978::AID-CNCR3>3.0.CO;2-D     Document Type: Article

References (33)

1. Thompson GB, Van Heerden JA. Adenocarcinoma of the stomach: are we making any progress? Lancet 1993;342:713-8.
2. Akoh AJ, McIntyre IMC. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Surg 1992;79:293-9.
3. Wils O, Klein HO, Wagener DJT, Bleiberg H, Reis H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Co-operative Group. J Clin Oncol 1991;9:827-31.
4. Coombes RC, Schein PS, Chilvers CED for the International Collaborative Cancer Group. A randomized trial comparing adjuvant flourouracil, doxorubicin and mitomycin with no treatment in operable gastric cancer. J Clin Oncol 1990; 8:1362-9.
5. Schuhmacher CH, Fink U, Bötcher HJ, Dittler H, Feussner K, Becker H. Neoadjuvant chemotherapy for locally advanced gastric cancer: a phase II study with etoposide, adriamycin and cisplatinum (EAP). Ann Oncol 1994;5(suppl 8):76 (abstr 380).
6. Kelson D, Karpeh D, Schwartz G, Saltz L, Ilson D, Huang Y. Neoadjuvant and postoperative chemotherapy for high-risk gastric cancer. Proc Am Soc Clin Oncol 1994;13:195(abstr 566).
7. Kelsen D, Atiq OT, Saltz L, Niedzwieck D, Ginn D, Chapman D. FAMTX versus etoposide, doxorubicin and cisplatin: a randomized trial in gastric cancer. J Clin Oncol 1992;10:541-8.
8. Massuti B, Cervantes A, Anton A, Aranda E, Diaz-Rubio A, Abad C. A Phase III multicenter randomized study in advanced gastric cancer: FLEP versus FAMTX: toxicity report. Ann Oncol 1994;5(suppl 8):76 (abstr 381).
9. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus best supportive care with best supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
10. Murad A, Santiago FF, Petroianou A, Rocha PRS, Rodrigues MAG, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
11. Cunningham D, Cahn A, Menzies-Gow N, Rosin RD, Mansi J, Dudley HAF. Epirubicin, cisplatin and 5-flourouracil (ECF) is highly effective in advanced gastric cancer. Proc Am Soc Clin Oncol 1990;9:123 (abstr 477).
12. McDonald J. Gastric cancer: chemotherapy of advanced disease. Haematol Oncol 1992;10:37-42.
13. Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high dose folinic acid. J Clin Oncol 1986;4:685-96.
14. Beer M, Cocconi G, Ceci G, Varini M, Cavalli F. A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 1983;19:717-20.
15. Cerasimo RJ, Hong WK. Epirubicin: a review of the pharmacology and adverse effects of an adriamycin analogue. J Clin Oncol 1986;4:425-34.
16. Etienne MC, Bernard S, Fischel JL, Formento J, Gioanni J, Santini F, et al. Dose reduction without loss of efficacy of 5-fluorouracil and cisplatin combined with folinic acid: in vitro studies on human head and neck carcinoma cell lines. Br J Cancer 1991;63:372-7.
17. Kyoto Research Group for Chemotherapy of Gastric Cancer. Randomized, comparative study of combination chemotherapy in advanced gastric cancer: 5-Fluorouracil and Cisplatin (FP) versus 5-Fluorouracil, Cisplatin and 4′-Epirubicin (FPEPIR). Anticancer Res 1992;12:1983-8.
18. Cocconi G. Chemotherapy of advanced gastric carcinoma: to be completely rewritten? Ann Oncol 1994;5:8-11.
19. Lokich JJ, Ahlgren JD, Gullo JJ, Phillips A, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989;7:425-32.
20. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T. A Phase II study in advanced gastric cancer using epirubicin and cisplatin in combination with continuous 5-FU (ECF). Ann Oncol 1994;5:609-16.
21. National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda (MD): Division of Cancer Treatment, National Cancer Institute, 1988.
22. Millar AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
23. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ. The European Organization for Research and Treatment of Cancer QLQ-C30: a Quality-of-Life instrument for use in the international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
24. Ringdal GI, Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res 1993;2:129-40.
25. Zaniboni A, Labianca R, Martignoni G, Signaroldi E, Piazza W, Legnani G, et al. ECF is an active feasible regimen for advanced gastric cancer. A GISCAD confirmatory study. Ann Oncol 1994;5 (suppl 8):79 (abstr 395).
26. Evans T, Glees J, Knight M, Leicester RJ, Fiennes A, Mansi J. The use of a new combination chemotherapy: epirubicin, cisplatin and continuous infusion 5-FU (ECF) in upper GI tumors. Ann Oncol 1992;3(suppl 5):14 (abstr 52).
27. Harper PG, Highley M, Houston S, Bright N, Walsh I, Owen WJ. Significant palliation of advanced gastro-oesophageal adenocarcinoma with laser endoscopy and combination chemotherapy. Proc Am Soc Clin Oncol 1992;11:164 (abstr 472).
28. Lerner A, Gonin R, Steele GD, Mayer RJ. Etoposide, doxorubicin and cisplatin chemotherapy for advanced gastric cancer: results of a phase II trial. J Clin Oncol 1992;10:536-40.
29. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heiniche A. Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-17.
30. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J. Preoperative chemotherapy in locally advanced and non-resectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989;7:1318-26.
31. Stewart JR, Hoff SJ, Johnson DH, Murray MJ, Butler DR, Elkins CC. Improved survival with neoadjuvant therapy and resection for adenocarcinoma of esophagus. Ann Surg 1993;218:571-8.
32. Lokich JJ, Shea M, Chaffey J. Sequential infusional 5-fluorouracil followed by concomitant radiation for tumors of the oesophagus and gastrooesophageal junction. Cancer 1987; 60:275-9.
33. Cervantes A, Villar-Grimalt A, Abad A, Anton-Torres A, Belon J, Dorta J. 5-FU, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Co-operative Group for Gastrointestinal Tumor Therapy. Ann Oncol 1993;4:753-7.